RECRUITING

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Talk to us

Conditions

ObesityOverweightChronic Low Back Pain (CLBP)Axial Predominant Low Back Pain

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Quick Facts

Study Start:2025-05-29
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07035093

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Have a history of axial-predominant low back pain
  2. * Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
  3. * Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
  4. * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
  1. * Have a non-axial origin low back pain
  2. * Have had botulinum or steroid injections to the spine within 1 year of screening
  3. * Have had trigger point injection to the spine within 6 months of screening
  4. * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days prior to screening
  5. * Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
  6. * Have a prior or planned surgical treatment for obesity
  7. * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

Contacts and Locations

Study Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
CONTACT
317-615-4559
clinical_inquiry_hub@lilly.com

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
STUDY_DIRECTOR
Eli Lilly and Company

Study Locations (Sites)

MD First Research - Chandler
Chandler, Arizona, 85286
United States
Tucson Orthopaedic Institute - North Wyatt Drive
Tucson, Arizona, 85712
United States
Ark Clinical Research - Fountain Valley
Fountain Valley, California, 92708
United States
St Joseph Heritage Healthcare
Fullerton, California, 92835
United States
Clinical Research Institute
Los Angeles, California, 90048
United States
Artemis Institute for Clinical Research
San Diego, California, 92103
United States
Alpine Clinical Research Center
Boulder, Colorado, 80301
United States
K2 Medical Research - Daytona Beach
Daytona Beach, Florida, 32114
United States
Suncoast Research Group
Miami, Florida, 33135
United States
IMA Clinical Research St. Petersburg
Saint Petersburg, Florida, 33704
United States
Care Access - Tampa
Tampa, Florida, 33625
United States
Charter Research - Lady Lake
The Villages, Florida, 32162
United States
Conquest Research
Winter Park, Florida, 32789
United States
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606
United States
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana, 70601
United States
MedVadis Research Corporation
Waltham, Massachusetts, 02451
United States
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706
United States
Clinvest Headlands Llc
Springfield, Missouri, 65807
United States
Center for Clinical Research
Winston-Salem, North Carolina, 27103
United States
Altoona Center For Clinical Research
Duncansville, Pennsylvania, 16635
United States
New Phase Research and Development
Knoxville, Tennessee, 37909
United States
FutureSearch Trials of Neurology
Austin, Texas, 78731
United States
Mercy Family Clinic
Dallas, Texas, 75211
United States
Houston Research Institute
Houston, Texas, 77079
United States
Spectrum Medical, Inc.
Danville, Virginia, 24541
United States

Collaborators and Investigators

Sponsor: Eli Lilly and Company

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-29
Study Completion Date2027-09

Study Record Updates

Study Start Date2025-05-29
Study Completion Date2027-09

Terms related to this study

Keywords Provided by Researchers

  • Axial Predominant Low Back Pain

Additional Relevant MeSH Terms

  • Obesity
  • Overweight
  • Chronic Low Back Pain (CLBP)